SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Group")
Notice of Full Year results and Investor Meet Company presentation
29 November 2024 - SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that the Group's full year results for the year to 30 June 2024 will be released on Wednesday 4 December 2024.
The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the Investor Relations section of the Group's website HERE.
Stuart Ashman, CEO and Manprit Randhawa, CFO will provide a live presentation via the Investor Meet Company platform at 10.00am GMT on Tuesday 10 December 2024.
The presentation is open to all existing and potential SkinBioTherapeutics shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9 December 2024, 09.00am GMT, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free via this link. Investors who already follow SkinBioTherapeutics plc on the Investor Meet Company platform will automatically be invited.
-Ends-
For more information please contact:
| SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO
| +44 (0) 191 495 7325
|
| Cavendish Capital Markets Limited (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales)
| +44 (0) 20 7220 0500
|
| Vigo Consulting (financial press) Rozi Morris
| +44 (0) 20 7390 0230 SkinBio@vigoconsulting.com
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.
The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements to modulate the immune system by harnessing the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the Group's first in-house product, AxisBiotix-Ps™, is a food supplement to address the symptoms of mild to moderate psoriasis.
The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
